SCHEMBL526575

SCHEMBL526575

Cc1cc(O)nn1-c1ccc2ccccc2c1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
SIGMAR1 Q99720 10/20 0.50
ALDH1A1 P00352 2/20 0.50
GAA P10253 1/20 0.50
HTR2B P41595 1/20 0.46
KCNH2 Q12809 1/20 0.44
RIPK2 O43353 1/20 0.43
MAPK10 P53779 3/20 0.42
NPC1 O15118 2/20 0.42
KDM4E B2RXH2 1/20 0.42
MAPK9 P45984 2/20 0.42
POLB P06746 1/20 0.42
LMNA P02545 1/20 0.41
HTR3A P46098 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31189136 1.00 RAB9A (0.54) RAB9ASMN1; SMN2CYP1A2CYP3A4CYP2C9
SCHEMBL15104833 0.91 RAB9A (0.57) RAB9ASMN1; SMN2CYP1A2CYP3A4CYP2C9
SCHEMBL1135364 0.83 HTR1A (0.46) RAB9ASMN1; SMN2CYP1A2CYP3A4CYP2C9
SCHEMBL1135440 0.83 CYP11B1 (0.46) RAB9ACYP1A2SIGMAR1ALDH1A1GAA
SCHEMBL577642 0.80 MAPK1 (0.56) RAB9ASMN1; SMN2CYP1A2CYP2C19NPC1
SCHEMBL1739906 0.80 POLB (0.56) RAB9ASMN1; SMN2CYP1A2CYP3A4CYP2C9
SCHEMBL528347 0.78 RAB9A (0.69) RAB9ASMN1; SMN2CYP1A2CYP3A4CYP2C9
SCHEMBL1135665 0.77 ALDH1A1 (0.39) RAB9ASMN1; SMN2SIGMAR1ALDH1A1GAA
SCHEMBL23401857 0.77 ALDH1A1 (0.45) RAB9ASMN1; SMN2CYP1A2CYP3A4CYP2C9
SCHEMBL1738878 0.76 RAB9A (0.50) RAB9ASMN1; SMN2CYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9035070-B2 Process for the preparation of 1-aryl-pyrazol-3-one intermediates useful in the synthesis of sigma receptors inhibitors Esteve Química, S.A. (ES) 2015-05-19 US disclosed
US-9035070-B2 Process for the preparation of 1-aryl-pyrazol-3-one intermediates useful in the synthesis of sigma receptors inhibitors Esteve Química, S.A. (ES) 2015-05-19 US disclosed
US-9035070-B2 Process for the preparation of 1-aryl-pyrazol-3-one intermediates useful in the synthesis of sigma receptors inhibitors Esteve Química, S.A. (ES) 2015-05-19 US disclosed
EP-2598469-B1 PROCESS FOR THE PREPARATION OF 1-ARYL-PYRAZOL-3-ONE INTERMEDIATES USEFUL IN THE SYNTHESIS OF SIGMA RECEPTORS INHIBITORS ESTEVE QUÍMICA S A (ES) 2014-07-23 EP disclosed
EP-2598469-B1 PROCESS FOR THE PREPARATION OF 1-ARYL-PYRAZOL-3-ONE INTERMEDIATES USEFUL IN THE SYNTHESIS OF SIGMA RECEPTORS INHIBITORS ESTEVE QUÍMICA S A (ES) 2014-07-23 EP disclosed
US-8492425-B2 5-methyl-1-(naphthalen-2-yl)-1H-pyrazoles useful as sigma receptor inhibitors LABORATORIES DEL DR. ESTEVE, S.A. (ES) 2013-07-23 US disclosed
US-20130184472-A1 Process for the Preparation of 1-ARYL-PYRAZOL-3-ONE Intermediates Useful in the Synthesis of SIGMA Receptors Inhibitors ESTEVE QUIMICA, S.A. (ES) 2013-07-18 US disclosed
US-20130184472-A1 Process for the Preparation of 1-ARYL-PYRAZOL-3-ONE Intermediates Useful in the Synthesis of SIGMA Receptors Inhibitors ESTEVE QUIMICA, S.A. (ES) 2013-07-18 US disclosed
US-20130184472-A1 Process for the Preparation of 1-ARYL-PYRAZOL-3-ONE Intermediates Useful in the Synthesis of SIGMA Receptors Inhibitors ESTEVE QUIMICA, S.A. (ES) 2013-07-18 US disclosed
EP-2598469-A1 PROCESS FOR THE PREPARATION OF 1-ARYL-PYRAZOL-3-ONE INTERMEDIATES USEFUL IN THE SYNTHESIS OF SIGMA RECEPTORS INHIBITORS Esteve Química, S.A. (ES) 2013-06-05 EP disclosed
EP-2418192-A1 Intermediates for the preparation of 1-aryl-pyrazol-3-one compounds useful as sigma receptors inhibitors Esteve Química, S.A. (ES) 2012-02-15 EP disclosed
WO-2012013755-A1 PROCESS FOR THE PREPARATION OF 1-ARYL-PYRAZOL-3-ONE INTERMEDIATES USEFUL IN THE SYNTHESIS OF SIGMA RECEPTORS INHIBITORS Esteve Química, S.A. (ES) 2012-02-02 WO disclosed
WO-2012013755-A1 PROCESS FOR THE PREPARATION OF 1-ARYL-PYRAZOL-3-ONE INTERMEDIATES USEFUL IN THE SYNTHESIS OF SIGMA RECEPTORS INHIBITORS Esteve Química, S.A. (ES) 2012-02-02 WO disclosed
US-20110118253-A1 5-METHYL-1-(NAPHTHALEN-2-YL)-1H-PYRAZOLES USEFUL AS SIGMA RECEPTOR INHIBITORS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2011-05-19 US disclosed
EP-2113501-A1 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors Laboratorios Del. Dr. Esteve, S.A. (ES) 2009-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118253-A1 5-METHYL-1-(NAPHTHALEN-2-YL)-1H-PYRAZOLES USEFUL AS SIGMA RECEPTOR INHIBITORS SIGMAR1, OPRM1, OPRK1 RAB9A 3233/4885SMN1; SMN2 1693/4885CYP1A2 25/4885
US-20130184472-A1 Process for the Preparation of 1-ARYL-PYRAZOL-3-ONE Intermediates Useful in the Synthesis of SIGMA Receptors Inhibitors SIGMAR1, OPRK1, OPRM1 RAB9A 4018/4885SMN1; SMN2 3992/4885CYP1A2 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.